Pharsight

Drugs that contain Osimertinib Mesylate

1. Tagrisso patents expiration

TAGRISSO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11524951 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(8 years from now)

US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(8 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020 ASTRAZENECA Pharmaceutical compositions comprising AZD9291
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-176) Apr 18, 2025
Orphan Drug Exclusivity(ODE-337) Dec 18, 2027
New Indication(I-941) Feb 16, 2027
Orphan Drug Exclusivity(ODE-102) Nov 13, 2022
New Indication(I-774) Apr 18, 2021
New Indication(I-853) Dec 18, 2023
Orphan Drug Exclusivity(ODE) Nov 13, 2022
New Chemical Entity Exclusivity(NCE) Nov 13, 2020

NCE-1 date: 14 November, 2019

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 l858r mutations in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of TAGRISSO before it's drug patent expiration?
More Information on Dosage

TAGRISSO family patents

Family Patents